Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

In vitro antifungal activity of fluconazole and voriconazole against non-Candida yeasts and yeast-like fungi clinical isolates.

Mandras N, Roana J, Scalas D, Fucale G, Allizond V, Banche G, Barbui A, Li Vigni N, Newell VA, Cuffini AM, Tullio V.

New Microbiol. 2015 Oct;38(4):583-7. Epub 2015 Oct 20.

2.

Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities of Candida glabrata: an assessment from the ARTEMIS DISK Global Antifungal Surveillance Program.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Barton R, Bijie H, Bille J, Chang SC, da Luz Martins M, Duse A, Dzierzanowska D, Ellis D, Finquelievich J, Gould I, Gur D, Hoosen A, Lee K, Mallatova N, Mallie M, Peng NG, Petrikos G, Santiago A, Trupl J, VanDen Abeele AM, Wadula J, Zaidi M; Global Antifungal Surveillance Group.

Diagn Microbiol Infect Dis. 2010 Jun;67(2):162-71. doi: 10.1016/j.diagmicrobio.2010.01.002. Epub 2010 Mar 24.

PMID:
20338711
3.

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA; Global Antifungal Surveillance Group.

J Clin Microbiol. 2010 Apr;48(4):1366-77. doi: 10.1128/JCM.02117-09. Epub 2010 Feb 17.

4.

Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, Klimko NN, Letscher-Bru V, Lisalova M, Muehlethaler K, Rennison C, Zaidi M; Global Antifungal Surveillance Group.

J Clin Microbiol. 2009 Jan;47(1):117-23. doi: 10.1128/JCM.01747-08. Epub 2008 Nov 12.

5.

Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ng KP, Colombo A, Finquelievich J, Barnes R, Wadula J; Global Antifungal Surveillance Group.

J Clin Microbiol. 2008 Mar;46(3):842-9. doi: 10.1128/JCM.02122-07. Epub 2008 Jan 16.

6.

Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Nagy E, Dobiasova S, Rinaldi M, Barton R, Veselov A; Global Antifungal Surveillance Group.

J Clin Microbiol. 2008 Feb;46(2):515-21. Epub 2007 Dec 12.

7.

Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, Fu W, Colombo AL, Rodriguez-Noriega E; Global Antifungal Surveillance Study.

J Clin Microbiol. 2007 Jun;45(6):1735-45. Epub 2007 Apr 18.

8.

Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.

Pfaller MA, Diekema DJ, Colombo AL, Kibbler C, Ng KP, Gibbs DL, Newell VA.

J Clin Microbiol. 2006 Oct;44(10):3578-82.

9.

Supplemental Content

Loading ...
Support Center